Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Medipharm Labs Corp T.LABS

Alternate Symbol(s):  MEDIF

MediPharm Labs Corp. is a Canada-based full-service pharmaceutical company. The Company specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products. Through its wholesale and white label platforms, the Company formulates, develops (including through sensory testing), processes, packages and distributes cannabis extracts and advanced cannabinoid-based products to domestic and international markets. It also provides GMP flower sourcing, packaging, and distribution services for select international clients. In addition, it cultivates cannabis to sell as dried flower, pre-roll and other cannabis products for the adult use and medical markets. It also sells metered dose inhalers and aerosol sublingual sprays. Through Harvest Medicine, it provides clinic services to Canadian patients requiring medical cannabis education and prescriptions.


TSX:LABS - Post by User

Post by QContinuum1on Nov 14, 2024 8:52am
111 Views
Post# 36312341

Disappointing

DisappointingNumbers do not suggest a real business.  Their channels suck and there is a Canadian implosion that won't recover.

But worst of all for me, is that Pidduck decided to dodge the tough discussion and not take any ownership of the regression.  Was he sitting in his corner suite all day just believing that all things were tickedy boo because Strachan told him so?  I held him and Hunter is very high regard, but dodging the call is a kitty move.

Germany is supposed to have a multi-hundred million dollar med market in 2024 alone and the best Medipharm can do with their powerhouse partner is a couple hundred k, Canadian no less.  No Brazil, no Drob pull through, no Epidiolex update, nothing. 

Heck, at least if SG&A went up because you bought a sales army, I could buy into that.  But nothing.



<< Previous
Bullboard Posts
Next >>